Biovie is trading 10.04% down at $2.02, extending weakness despite biotechnology and major U.S. indexes moving higher on September 2, 2026; no company-specific announcement explaining the decline was identified.
- BioVie’s latest material update, released August 31, stated it completed the treatment phase of the ADDRESS-LC trial.
- Topline data is expected before the end of September 2026.
- The cause remains unclear as the stock moves opposite its sector.